IL5 and eosinophilic esophagitis: The IL-5-targeting agents mepolizumab and reslizumab, commonly prescribed for severe eosinophilic asthma, showed histologic improvements in eosinophilic esophagitis (e.g., reduction in eosinophils), but failed to induce symptomatic improvement [42, 43].